



# Examining Models for the Pharmacokinetics of Perfluorooctanoic acid


**John Wambaugh, Woodrow Setzer, and Hugh Barton**  
National Center for Computational Toxicology

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY



Office of Research and Development  
National Center for Computational Toxicology


# Perfluoroalkyl acids (PFAA)



Straight chain PFOA

- Perfluorooctanoic acid (PFOA) is a perfluorinated fatty acid analog (Other PFAAs include PFOS and PFNA)
- Found throughout the environment (Lau et al., 2007)
- Measurable levels in the blood serum of most people in the United States (Calafat et al., 2007)



- Production of PFOS was halted in 2002 in the United States (Betts, 2007) – some evidence that human serum levels decreasing (Olsen et al., 2007)
- Industry will work toward eliminating emissions and product content of PFOA and related chemicals by 2015
- Replacement chemicals are typically shorter length carbon chain compounds
- PFOA is not metabolized, making PK modeling somewhat “easier”




Caprylic acid

# Pharmacokinetics of PFAA

- PFOA has a human serum half-life of roughly four years
- Plasma half lives vary with species and sex: female rats (~4 hours), male rats (~4 days), and male and female monkeys (~1 month)
- Despite slow half-life, PFOA levels equilibrate rapidly in mice



# The Saturable Resorption Model




Proposed by Andersen et al. (2006) for both PFOS and PFOA, based upon PFOA data that showed larger doses did not lead to larger serum concentrations

Possible mechanism is that saturable transporters (OATP1 and OAT3 – Katakura et al., 2007) recover the compounds from the filtrate before they are excreted (Ullrich et al., 1982)


# Single and Repeated Doses Reconciled

## Female CD1 Mice


Single doses of 1, 10, 60 mg/kg



7- and 17-day repeat doses of 20 mg/kg



# Uncertainty in Parameter Estimates




		Mean	SD
$V_{cc}$	L/kgBW	0.1092	0.0080
$k_{12}$	1/h	0.2173	0.1351
$k_{21}$	1/h	0.0109	0.0075
$V_{tc}$	L/kgBW	2.1785	0.6059
$Q_d$	L/h	0.0006	0.0004
$Q_{filc}$	fraction	0.6346	0.9424
$T_{mc}$	mg/h/kgBW	94.0483	142.0120
$K_T$	mg/L	0.0015	0.0022







- $V_t$  and  $Q_{fil}$  are very large
- Saturable transport parameters have large uncertainty
- Note that only 6 PK parameters were estimated –  $k_{12}$ ,  $k_{21}$ ,  $V_{tc}$ , and  $Q_d$  are not independent

# Bayesian Analysis of Dynamic Models

- Using MCMC sampler developed for R by Garcia, Wambaugh, Davis, and Setzer
- Analyzing a non-hierarchical model – single set of parameters to describe all animals
- Can use multiple data types/sources by estimating separate measurement variances
- Minimally informative priors on parameter values
- Can run several hundred thousand samples in a day on a desktop PC




# Bayesian Analysis of Saturable Resorption Model Parameters




# Accumulation in Liver of Male CD1 Mouse?

## Single Dose

Male Mouse




Female Mouse



- Andersen et al. model explains serum, but not necessarily liver
- Evidence for sex-dependent distribution

# Similar for Perfluorononanoic Acid (PFNA)?

## Single Dose



- Tatum et al. (Poster 505, Tuesday 9:00 AM)
- Gender difference may be general for moderate-length PFAA

# Reconciling Male and Female PK

- Male and female mice have roughly similar serum kinetics
  - females:  $t_{1/2} = 15.6$  days,  $V_d = 0.135$  L/kg
  - males:  $t_{1/2} = 21.7$  days,  $V_d = 0.226$  L/kg
- Different liver levels
- What explains the difference:
  - Offsetting differences in partitioning?
  - Different renal clearances (accumulation in filtrate)?
  - Differences in liver transporters (*e.g.* OAT, OATP)?
- If we want to include kidney and liver data from Lou et al. (2009) then we need a PBPK model

# Physiologically-Based PK for PFOA

## Physiologic Values:

$$Q_c, Q_l, Q_k, Q_{gf}, Q_{ur},$$

$$Q_r = Q_c - Q_l - Q_k$$

$$V_b, V_l, V_r, V_k, V_f$$

## Assumed chemical specific values:

free = 0.02 (Andersen et al. (2006))

$R_{b2p} = 0.48$  (Ehresman et al. (2006))


$$k_{ad} = 1$$

## Estimated values:

$$K_{l2p}, K_{r2p}, K_{k2p},$$

$$T_m, K_T,$$


Kidney similar to Ethylene Glycol  
PBPK by Corley et al. (2000)



# Tissue-specific Predictions


Single Dose 1 or 10 mg/kg

Lou et al. (2009)




# Tissue-specific Predictions

7- and 17-Day 20 mg/kg  
Lau et al. (2006) and Lou et al. (2009)




# Male Results

Single Dose 1 or 10 mg/kg  
Lou et al. (2009)



7-Day 1 or 10 mg/kg  
Wolf et al. (2008)



**Blood Sera**

**Liver**





**Kidney**

# Gender Difference is in Distribution



**Female**

**Male**

## Partition Coefficients



## Saturable Renal Resorption



# Future Directions


- Difference between CD1 mouse genders appears to be related to a process other than saturable resorption in the kidney
- Possible mechanisms include specific binding or transporter differences in the liver
- Additional complexity introduces additional parameters which must be estimated
- Can discriminate between models using Bayesian Information Criterion (BIC) if comparing to the same data set
- PFAA is complicated

# Acknowledgments

*Thanks to the NCCT “statistics and PBPk group”!*

## **Past**

Hugh Barton  
Inchio Lou  
Miyoung Yoon



## **Current**

Woody Setzer  
Chester Rodriguez  
Ramon Garcia  
Jimena Davis

## **National Health and Environmental Effects Laboratory**

Christopher Lau  
Roger Hanson  
Dan Zehr  
Katoria Tatum

## **National Exposure Research Laboratory**

Andy Lindstrom  
Mark Strynar

DISCLAIMER: The contents of this presentation do not necessarily reflect EPA policy.